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The human lens contains three kynurenine UV filters, 3-hydroxykynurenine O-β-D-
glucoside (3OHKynG), kynurenine (Kyn) and 3-hydroxykynurenine (3OHKyn), and it 
absorbs UV light in the 300-400 nm region due to their presence. UV filters may also 
prevent UV-induced photodamage to the retina and lens. After middle age, the UV 
filters, 3OHKynG and Kyn become bound progressively to proteins in the centre of our 
lenses. This feature is, in part, responsible for normal age-dependant human lens 
colouration.  
 
To provide proof that 3OHKyn is bound to normal human lenses, model studies were 
undertaken. Cysteine (Cys), histidine (His) and lysine (Lys) residues in lens proteins 
had been previously shown to bind to UV filters in vivo, therefore adducts of these 
amino acids and 3OHKyn were synthesised and characterised by mass spectrometry, 
fluorescence, UV-visible and NMR spectroscopy in Chapter 2. The stability properties 
of each of the 3OHKyn amino acid adducts were also determined, with incubations 
performed at pH 4.0 and pH 7.2. 3OHKyn-t-Boc-His was identified as the most stable 
of the three adducts. 3OHKyn-t-Boc-Lys and 3OHKyn-Cys both decomposed at pH 7.2 
forming numerous oxidation products. The stability of each adduct to acid hydrolysis 
was also examined.  
 
In Chapter 3, calf lens protein was incubated with 3OHKyn, and acid hydrolysis showed 
that Cys was the primary site of modification when the incubation was undertaken at pH 
7.2. However, when the incubation was undertaken at a higher pH (for example, pH 
9.5), 3OHKyn readily modified Cys, His and Lys residues. Previously acid hydrolysis 
of human lens protein had identified Kyn attachment to the proteins. However, acid 
hydrolysis was not an appropriate method for detecting 3OHKyn attached to human lens 
proteins because 3OHKynG is also bound to human lens proteins. Therefore, a new 
assay was developed, and it was found that 3OHKyn does indeed bind to human lens 
proteins in an age-dependant manner. The assay also provides data for 3OHKynG and 
Kyn attachment to human lens proteins. 
 
xxii 
In Chapter 3, α-crystallin was also incubated with 3OHKyn under low oxygen tension, 
and the findings from this study showed that 3OHKyn modified the Cys residue in αA-
crystallin. In addition, oxidation of methionine and tryptophan was observed. Age-
related nuclear cataract is associated with colouration, insolubilisation and extensive 
oxidation of Cys and methionine residues. It appears that 3OHKyn in the lens may 
promote the oxidation and modifications of proteins, and may contribute to oxidative 
stress in the human lens.   
 
In Chapter 4, the aim was to examine if 3OHKyn could act as a crosslinker of cataract 
lens proteins. 3OHKyn is known to readily oxidise and yield highly reactive species. It 
was therefore proposed that 3OHKyn bound to lens proteins could promote 
crosslinking, insolubilisation and colouration of lens proteins following formation of 
oxidised species. 3OHKyn amino acid adducts were incubated with excess amino acids, 
and the resulting products examined. These compounds may be analogous to those that 
would form in a cataract lens. In addition, 3OHKyn-modified protein was incubated and 
the products were examined by SDS-PAGE, fluorescence spectroscopy and mass 
spectrometry. Results showed that 3OHKyn, under the conditions used, does not 
crosslink lens protein. Proof of the hypothesis that 3OHKyn crosslinks proteins in the 
lens requires the isolation of characteristic chemical markers from cataract lens proteins 
that contain the modified 3OHKyn molecules. 
 
In Chapter 5, the aim was to isolate novel compounds from the hydrolysates of human 
cataract lens proteins and to determine their chemical properties. 
 
Overall this thesis provides evidence that 3OHKyn plays a role in the post-translational 
modification of normal human lens proteins, and it also provides preliminary data on the 
role of 3OHKyn in human cataract. 
 
 
 
